2026 International Spring Forum
April 15, 2026 | 12:00 PM EST
Webinar
A Combination Treatment for Patients with Advanced Renal Cell Carcinoma
Date: January 29, 2026 | 2:00 PM

Date: Thursday, January 29 | 2 p.m. EST
Presenter: Brittney Carden, PharmD | USA Health Mitchell Cancer Institute
Cabozantinib (CABOMETYX®) + nivolumab (OPDIVO®) is a first-line option in advanced renal cell carcinoma, but the practical questions show up fast: what the data supports, what to watch for early, and how to manage adverse reactions without losing momentum on treatment.
This session will cover:
- Key information on the use of cabozantinib + nivolumab in first-line advanced RCC (aRCC)
- Efficacy and safety data for cabozantinib + nivolumab in first-line aRCC
- Monitoring and management of select adverse reactions with cabozantinib monotherapy and cabozantinib + nivolumab (including considerations for OPDIVO Qvantig™ [nivolumab and hyaluronidase-nvhy])
- Resources available to providers, patients, and caregivers
For additional information or login assistance, reach out to NCODA’s Jonathan Rivera.
Login to Watch this Webinar
To watch the live webinar, login to your account or register to gain access to our exclusive content.
Additional Upcoming Webinars
Upcoming Webinar
Team-Based Oncology Care: Supportive Communication, Lymphoma Safety Workflows + EV-303 Insights
February 19, 2026 | 2:00 PM
Upcoming Webinar
Pharmacy Perspectives: Lifestyle Strategies & CTCAE Updates
February 24, 2026 | 5:00 PM